|Bid||7.03 x 1800|
|Ask||7.34 x 1000|
|Day's range||6.90 - 7.39|
|52-week range||3.28 - 8.85|
|Beta (5Y monthly)||0.31|
|PE ratio (TTM)||N/A|
|Earnings date||20 Feb 2023 - 24 Feb 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||11.27|
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Xeris Biopharma (XERS) enters into a research collaboration with Horizon Therapeutics to develop a ready-to-use variant of teprotumumab to treat thyroid eye disease.
To get a sense of who is truly in control of Esperion Therapeutics, Inc. ( NASDAQ:ESPR ), it is important to understand...